Novartis AG might soon be able to reclaim some of the kudos it once received for developing groundbreaking transplant-enabling therapies like ciclosporin, through its pioneering of a new class of potential products now in early clinical development.
The Basel, Switzerland-based multinational has an impressive heritage in the organ transplant sector going back more than 30 years, but...